Company intelligence
Guardant Health
Conquering Cancer With Data
About Guardant Health
Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, we're transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant® tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. Important Note for Job Applicants: Guardant Health is aware of recruiting scams where unauthorized individuals use the company's name in fraudulent emails, job postings, and social media messages. Please note that Guardant Health will never ask for money or credit card information during the job application process, nor does the company communicate with candidates via online chatrooms or personal email accounts such as Gmail or Hotmail.
Verified activity
Signals from Guardant Health
13 published signals
Legal & Regulatory
Guardant Health received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer
Reported by Guardant Health
Legal & Regulatory
Guardant Health announced that the Guardant360 CDx assay was approved by the FDA as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with camizestrant.
Reported by Jason Gottwals
Presence & Recognition
Guardant Health was named one of America’s Most Innovative Businesses for 2027 with a five-star rating awarded to only 10 companies in the biotechnology category.
Reported by Guardant Health
Presence & Recognition
Guardant Health teams from Palo Alto and Redwood City filled backpacks with supplies for local students supported by Peninsula Bridge and Ayudando Latinos A Soñar
Reported by Guardant Health
Research & Knowledge
Guardant Health reported that the dual oral regimen showed encouraging activity in KRAS G12C-mutated metastatic colorectal cancer patients.
Reported by Jason Gottwals
People
Guardant Health is hiring a Senior Director, People Business Partner, and Global Employee Relations to join the team and help shape the People strategy and Guardant Health's growth.
Reported by Joseph Romano
People
Guardant Health is hiring a Senior Director, People Business Partner, and Global Employee Relations to join the team and help shape the People strategy and growth.
Reported by Erin Bennardo, SHRM-CP
Research & Knowledge
Guardant Health reported that the participation rate for the colorectal cancer screening campaign in France is very low, with less than 35% of the target population (50-74 years old).
Reported by Shirine Benhenda, PhD
People
Guardant Health employee Genavieve is currently pursuing her senior year of undergrad at U Miami, majoring in exercise physiology with a minor in psychology.
Reported by Tisha (Milla) Newton
Customers & Market
Guardant Health is leading the way to make colon cancer screening more accessible to more patients.
Reported by Jaime Anderly
Customers & Market
Guardant Health expanded coverage of its FDA-approved Shield blood test to eligible policyholders beginning November 15, with approximately 90 million people ages 45 and older having coverage for the test.
Reported by Guardant Health
People
Guardant Health promoted Beau Santos to Senior Account Executive.
Reported by Beau Santos
Presence & Recognition
Guardant Health co-CEO AmirAli Talasaz reflects on the lives and legacies of those who have passed from colorectal cancer.
Reported by Guardant Health